Developing new drugs for children with cancer is a complicated multi-step process that involves many different groups (academic researchers, pharmaceutical industry, patient advocates, regulatory authorities, …). There is a need to improve the efficiency of this process and fulfil the unmet needs of children with cancer.
What is our mission?
Accelerating drug development for childhood cancer through education.
ALADDIN is an educational program on strategic and regulatory science in paediatric oncology drug development to foster expertise and strengthen true multi-stakeholder collaboration. Through this project, individuals from various disciplines have the opportunity to learn about how to effectively navigate the regulatory science behind paediatric cancer drug development.
How does ALADDIN work?
Course on Regulatory Science in Paediatric Oncology Drug Development
360° Multi-stakeholder rotation
ACCELERATE Research Fellowship
Open access online educational portal